Education
About Us
Working with TipRanks
Follow Us
PMV Pharmaceuticals (PMVP)
NASDAQ:PMVP
PMVP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.81 - $1.82
Previous CloseN/A
Volume81.53K
Average Volume (3M)324.25K
Market Cap
$56.11M
Enterprise Value$1.71B
Total Cash (Recent Filing)$160.39M
Total Debt (Recent Filing)$1.11M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Aug 07, 2025EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding51,952,680
10 Day Avg. Volume388,283
30 Day Avg. Volume324,253
Financial Highlights & Ratios
PEG Ratio-11.88
Price to Book (P/B)-22.89
Price to Sales (P/S)0.00
P/FCF Ratio-72.74
Enterprise Value/Market Cap30.45
Enterprise Value/Revenue527.98
Enterprise Value/Gross Profit-4.59K
Enterprise Value/Ebitda-5.28
Forecast
1Y Price Target
$5.00Price Target Upside362.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
PMV Pharmaceuticals News
PremiumCompany Announcements
PMV Pharmaceuticals Holds 2025 Annual Stockholder Meeting
PremiumCompany Announcements
PMV Pharmaceuticals Reports Q1 2025 Financial Results
PremiumCompany Announcements
PMV Pharmaceuticals Reports Progress in Clinical Trials
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressEnrollment into the pivotal Ph2 portion of the PYNNACLE trial evaluating rezatapopt monotherapy in TP53 Y220C and KRAS WT advanced solid tumors remains on track.
Financial StabilityPMV ended 2024 with $183.3M in cash, which in our view should fund operations to end-2026.
Bears Say
Clinical Data RisksRisks include negative PC14586 clinical data, delays in moving candidates into advanced trials, and setbacks in later-stage studies.
Market Deployment ChallengesThere is a low probability of PC14586 monotherapy deployment in a tumor-agnostic fashion due to the minimum requirement criteria.
Ownership Overview
3.02% Insiders
8.55% Mutual Funds
54.77% Other Institutional Investors
29.50% Public Companies and
Individual Investors
PMVP FAQ
What was PMV Pharmaceuticals’s price range in the past 12 months?
PMV Pharmaceuticals lowest stock price was $0.81 and its highest was $1.82 in the past 12 months.
What is PMV Pharmaceuticals’s market cap?
PMV Pharmaceuticals’s market cap is $56.11M.
When is PMV Pharmaceuticals’s upcoming earnings report date?
PMV Pharmaceuticals’s upcoming earnings report date is Aug 07, 2025 which is in 52 days.
How were PMV Pharmaceuticals’s earnings last quarter?
PMV Pharmaceuticals released its earnings results on May 09, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.372 by $0.032.
Is PMV Pharmaceuticals overvalued?
According to Wall Street analysts PMV Pharmaceuticals’s price is currently Undervalued.
Does PMV Pharmaceuticals pay dividends?
PMV Pharmaceuticals does not currently pay dividends.
What is PMV Pharmaceuticals’s EPS estimate?
PMV Pharmaceuticals’s EPS estimate is -0.39.
How many shares outstanding does PMV Pharmaceuticals have?
PMV Pharmaceuticals has 51,952,680 shares outstanding.
What happened to PMV Pharmaceuticals’s price movement after its last earnings report?
PMV Pharmaceuticals reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.372. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PMV Pharmaceuticals?
Currently, no hedge funds are holding shares in PMVP
PMV Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (362.96% Upside)
$5.00 (362.96% Upside)
Hedge Fund Trend
Decreased
By 322.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.93%
12-Months-Change
Fundamentals
Return on Equity
-32.66%
Trailing 12-Months
Asset Growth
-27.98%
Trailing 12-Months
Company Description
PMV Pharmaceuticals
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
PMVP Stock 12 Month Forecast
Average Price Target
$5.00
▲(362.96%Upside)
Technical Analysis
PDS Biotechnology
―
CytomX Therapeutics
―
Cue Biopharma
―
Sutro Biopharma
―
Fractyl Health, Inc.
―